Table 2.
Clinical characteristics of consecutive patients treated prior to and following implementation of the risk-stratified pancreatectomy clinical pathways (N = 375).
| Clinical Factor, n (%) | Historic (n=315) | RSPCP (n=60) | P-value |
|---|---|---|---|
| Median Age, years (IQR) | 62 (55-69) | 60 (52-72) | .809 |
| Sex, male | 181 (57%) | 32 (53%) | .554 |
| Obese, BMI ≥ 30 | 89 (28%) | 11 (18%) | .111 |
| DM | 71 (23%) | 12 (20%) | .664 |
| Comorbidity | .078 | ||
| None | 83 (26%) | 18 (30%) | |
| Mild | 116 (37%) | 30 (50%) | |
| Moderate | 79 (25%) | 9 (15%) | |
| Severe | 37 (12%) | 3 (5%) | |
| PDAC | 147 (47%) | 26 (43%) | .635 |
| PDAC, radiographic stage | .546 | ||
| Potentially resectable | 104 (69%) | 18 (69%) | |
| Borderline resectable | 41 (27%) | 6 (23%) | |
| Locally advanced | 5 (3%) | 2 (8%) | |
| Preoperative therapy | .573 | ||
| None | 171 (54%) | 37 (62%) | |
| Chemo alone | 32 (10%) | 5 (8%) | |
| Chemoradiation +/−chemo | 112 (36%) | 18 (30%) | |
| Operation | |||
| PD | 202 (64%) | 39 (65%) | .897 |
| DP | 113 (36%) | 21 (35%) | |
| Open | 103 (91%) | 14 (67%) | .002 |
| Minimally invasive | 10 (9%) | 7 (33%) | |
| Vascular resection | .707 | ||
| Vein | 70 (22%) | 10 (17%) | |
| Artery | 2 (1%) | 0 (0%) | |
| Vein + artery | 13 (4%) | 3 (5%) | |
| Risk Group | .895 | ||
| Low-risk PD | 142 (45%) | 26 (43%) | |
| High-risk PD | 60 (19%) | 13 (22%) | |
| DP | 113 (36%) | 21 (35%) |
RSPCP, risk-stratified pancreatectomy clinical pathways; IQR, interquartile range; BMI, body mass index; DM, diabetes mellitus; PDAC, pancreatic ductal adenocarcinoma; PD, pancreatoduodenectomy; DP, distal pancreatectomy; chemo, systemic chemotherapy; LOS, length of stay.